J
Jonas Eriksson
Researcher at Uppsala University
Publications - 72
Citations - 3028
Jonas Eriksson is an academic researcher from Uppsala University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 25, co-authored 61 publications receiving 2672 citations. Previous affiliations of Jonas Eriksson include VU University Amsterdam & Laurentian University.
Papers
More filters
Journal ArticleDOI
Whole-genome resequencing reveals loci under selection during chicken domestication
Carl-Johan Rubin,Michael C. Zody,Michael C. Zody,Jonas Eriksson,Jennifer R. S. Meadows,Ellen Sherwood,Matthew T. Webster,Liang Jiang,Max Ingman,Ted Sharpe,Sojeong Ka,Finn Hallböök,Francois Besnier,Örjan Carlborg,Bertrand Bed'Hom,Michèle Tixier-Boichard,Per Jensen,Paul B. Siegel,Kerstin Lindblad-Toh,Kerstin Lindblad-Toh,Leif Andersson,Leif Andersson +21 more
TL;DR: The authors used massively parallel sequencing to identify selective sweeps of favorable alleles and candidate mutations that have had a prominent role in the domestication of domestic chickens and their subsequent specialization into broiler (meat-producing) and layer (egg-consuming) chickens.
Journal ArticleDOI
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A.M. van der Veldt,Mark Lubberink,Mark Lubberink,Idris Bahce,Maudy Walraven,Michiel P. de Boer,Henri N.J.M. Greuter,N. Harry Hendrikse,Jonas Eriksson,Albert D. Windhorst,Pieter E. Postmus,Henk M.W. Verheul,Erik H. Serné,Adriaan A. Lammertsma,Egbert F. Smit +14 more
TL;DR: In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr and there was no evidence for a substantial improvement in drug delivery to tumors.
Journal ArticleDOI
A Comparative Study of the Hypoxia PET Tracers [F-18] HX4, [F-18] FAZA, and [F-18] FMISO in a Preclinical Tumor Model
S. Peeters,Catharina M.L. Zegers,Natasja G. Lieuwes,Wouter van Elmpt,Jonas Eriksson,Guus A.M.S. van Dongen,Ludwig Dubois,Philippe Lambin +7 more
TL;DR: Each hypoxia PET tracer frequently used in the clinic has its own strengths and, depending on the question to be answered, a different tracer can be put forward.
Journal ArticleDOI
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
Konstantinos Chiotis,Laure Saint-Aubert,Irina Savitcheva,Vesna Jelic,Pia Andersen,My Jonasson,My Jonasson,Jonas Eriksson,Jonas Eriksson,Mark Lubberink,Ove Almkvist,Ove Almkvist,Ove Almkvist,Anders Wall,Anders Wall,Gunnar Antoni,Gunnar Antoni,Agneta Nordberg,Agneta Nordberg +18 more
TL;DR: The tau-specific PET tracer [18F]THK5317 images in vivo show the expected regional distribution of tau pathology, which contrasts with the different patterns of hypometabolism and amyloid-beta deposition.
Journal ArticleDOI
Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients
Sandeep S.V. Golla,Ronald Boellaard,Vesa Oikonen,Anja Hoffmann,Bart N.M. van Berckel,Albert D. Windhorst,Jere Virta,Merja Haaparanta-Solin,Pauliina Luoto,Nina Savisto,Olof Solin,Ray Valencia,Andrea Thiele,Jonas Eriksson,Jonas Eriksson,Robert C. Schuit,Adriaan A. Lammertsma,Juha O. Rinne +17 more
TL;DR: The data suggest that [18F]DPA-714 cannot be used for separating individual AD patients from heathy subjects, but further studies including TSPO binding status are needed to substantiate these findings.